Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Diabetic Macular Edema/Diabetic Retinopathy | Current Treatment | US | 2016

Login to access report north_east
Contact sales account_box

Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal pharmacotherapy product approvals across different drug classes in Europe since 2011. Although laser photocoagulation has long been the standard of care for patients with the most advanced stages of DR, recent clinical trial results suggest that intravitreal pharmacotherapy injections may be effective treatment for this broader patient population as well. The Diabetic Retinopathy/Diabetic Macular Edema | Current Treatment Overview provides a synopsis of current treatment goals, key therapies, and medical practice in the United States and EU5 markets for DR and DME. The Diabetic Retinopathy/Diabetic Macular Edema | Current Treatment | EU detailed, expanded analysis offers a snapshot of how ophthalmologists in the EU5 are currently treating DR and DME patients, with a particular focus on use of intravitreal vascular endothelial growth factor (VEGF) inhibitors and intravitreal corticosteroid implants, as well as insight into the factors driving such prescribing habits. 

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east